What is the main mechanism of action of sparsentin?

Sparsentan, a drug developed byTravere Therapeutics, is mainly used to treat primary immunoglobulin A nephropathy (IgAN), which is a relatively common type of kidney disease in my country. The mechanism of action of sparsentane is unique and complex. It mainly exerts its therapeutic effect through a dual inhibitory mechanism.

Sparsentan is a molecule that acts as a dual antagonist of endothelintype a receptor (ETAR) and angiotensin II (Ang II) type 1 receptor (AT1R). It has two clinically proven mechanisms of action and selectively blocks the effects of two potent vasoconstrictors and mitogens, Ang II and endothelin 1 (ET-1), at their respective receptors. ET-1 and Ang II are involved in the pathogenesis of immunoglobulin A nephropathy (IgAN), a disease characterized by increased production of galactose-deficient IgA1 (Gd-IgA1) antibodies. Gd-IgA1 antibodies cause mesangial cell activation and proliferation, which stimulate and are stimulated by the production of ET-1 and Ang II. The pathological cycle of IgAN results in damage to the glomerular filtration barrier, followed by proteinuria and hematuria. By acting as both an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA), sparsentan can reduce proteinuria in patients with IgAN. Sparsetan has high affinity for both ETAR (Ki=12.8 nM) and AT1R (Ki=0.36 nM), and its selectivity for these receptors is more than 500 times that of endothelin type B and angiotensin II subtype 2 receptors.

In clinical studies, the efficacy of sparsentane has been further verified. For example, in an international, randomized, double-blind, active-controlled study that included 404 patients with IgA nephropathy, the results showed that the change in the urine protein/creatinine ratio of the sparsentan group from baseline was statistically significant, resulting in a relative reduction of 41% between groups, which fully demonstrated the effectiveness of sparsentan in the treatment of IgAN.

In summary, sparsentan exerts a significant therapeutic effect on primary immunoglobulin A nephropathy through a dual inhibitory mechanism, namely blocking endothelinA receptors and angiotensin type II type 1 receptors, providing a new treatment option for such patients.

xa0

Reference link: https://go.drugbank.com/drugs/DB12548